Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

NCT00117650 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

289

Enrollment

INDUSTRY

Sponsor class

Conditions

Intermittent Claudication
Peripheral Vascular Disease
Atherosclerosis

Interventions

BIOLOGICAL: Ad2/HIF-1α/VP16
BIOLOGICAL: Ad2/HIF-1α/VP16
BIOLOGICAL: Ad2/HIF-1α/VP16
OTHER: Saline (Placebo Control)

Sponsor

Genzyme, a Sanofi Company